Heba R. Alrefaey

Ms. Heba R. Alrefaey

Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida, USA
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2025 in Nanomaterials
Verified
Journal Article
Open access
PDF file
SMShaymaa Mohamed
Shaymaa Mohamed
AEAsmaa M. Elsherbini
Asmaa M. Elsherbini
Heba R. AlrefaeyHeba R. Alrefaey
Heba R. Alrefaey
KEkareem Abd El-Rahman
kareem Abd El-Rahman
AMAlshaimaa Moustafa
Alshaimaa Moustafa
SSSally A. Sabra
Sally A. Sabra
Gum Arabic (GA), or acacia gum, refers to the dried exudate produced by certain Acacia trees. GA is composed mainly of a mixture of polysaccharides and glycoproteins, with proportions that can slightly differ from one species to another. It is commonly utilized in the food and pharmaceutical industries as a stabilizer or an emulsifier owing to its biocompatibility, hydrophilicity, and antibacterial properties. In addition, GA can be manipulated as it possesses many functional groups that can be used in grafting, cross-linking, or chemical modifications to add a new feature to the developed material. In this review, we highlight recent GA-based formulations, including nanoparticles, hydrogels, nanofibers, membranes, or scaffolds, and their possible applications in tissue regeneration, cancer therapy, wound healing, biosensing, bioimaging, food packaging, and antimicrobial and antifouling membranes.

28 May 2021 in Biological Research
Verified
Journal Article
Open access
PDF file
Heba R. AlrefaeyHeba R. Alrefaey
Heba R. Alrefaey
ANAl-Sayeda A. Newairy
Al-Sayeda A. Newairy
MWMayssaa M. Wahby
Mayssaa M. Wahby
CAChris Albanese
Chris Albanese
MEMohamed Elkewedi
Mohamed Elkewedi
ASAhmed S. Sultan
Ahmed S. Sultan
Background: Recently, there is increasing awareness focused on the identification of naturally occurring anticancer agents derived from natural products. Manuka honey (MH) has been recognized for its biological properties as antimicrobial, antioxidant, and anticancer properties. However, its antiproliferative mechanism in hepatocellular carcinoma is not investigated. The current study focused mainly on investigating the molecular mechanism and synergistic effect of anticancer properties of MH on Doxorubicin (DOX)-mediated apoptotic cell death, using two different p53 statuses (HepG2 and Hep3B) and one non-tumorigenic immortalized liver cell line. Results: MH treatment showed a proliferative inhibitory effect on tested cells in a dose-dependent manner with IC50 concentration of (6.92 ± 0.005%) and (18.62 ± 0.07%) for HepG2 and Hep3B cells, respectively, and induced dramatic morphological changes of Hep-G2 cells, which considered as characteristics feature of apoptosis induction after 48 h of treatment. Our results showed that MH or combined treatments induced higher cytotoxicity in p53-wild type, HepG2, than in p53-null, Hep3B, cells. Cytotoxicity was not observed in normal liver cells. Furthermore, the synergistic effect of MH and Dox on apoptosis was evidenced by increased annexin-V-positive cells and Sub-G1 cells in both tested cell lines with a significant increase in the percentage of Hep-G2 cells at late apoptosis as confirmed by the flow cytometric analysis. Consistently, the proteolytic activities of caspase-3 and the degradation of poly (ADP-ribose) polymerase were also higher in the combined treatment which in turn accompanied by significant inhibitory effects of pERK1/2, mTOR, S6K, oncogenic β-catenin, and cyclin D1 after 48 h. In contrast, the MH or combined treatment-induced apoptosis was accompanied by significantly upregulated expression of proapoptotic Bax protein and downregulated expression of anti-apoptotic Bcl-2 protein after 48 h. Conclusions: Our data showed a synergistic inhibitory effect of MH on DOX-mediated apoptotic cell death in HCC cells. To our knowledge, the present study provides the first report on the anticancer activity of MH and its combined treatment with DOX on HCC cell lines, introducing MH as a promising natural and nontoxic anticancer compound.

1 June 2026 in Biomedical Materials
Verified
Journal Article
Open access
Heba R. AlrefaeyHeba R. Alrefaey
Heba R. Alrefaey
FMFayed A K Megahed
Fayed A K Megahed
KAKareem Abdelrahman
Kareem Abdelrahman
AEAsmaa M Elsherbini
Asmaa M Elsherbini
AWAl-Hassan Soliman Wadan
Al-Hassan Soliman Wadan
Ahmed El-GendyAhmed El-Gendy
Ahmed El-Gendy
Cancer is among the fatal diseases that affect individuals worldwide. According to World Health Organization statistics, if the current trends continue, the world will see a significant increase in cancer cases over the next two decades, leading to a staggering number of deaths by 2040. Therefore, finding innovative strategies for cancer treatment has become a critical priority. Recently, magnetic nanoparticles (MNPs) have been widely applied in cancer diagnosis via magnetic resonance imaging, in hyperthermia, and in drug delivery to specific organs due to their unique physicochemical properties. However, the most significant challenge of using MNPs is ensuring compliance with in vivo nano-safety regulations. MNP characteristics necessary for biomedical applications, followed by a description of their physical, chemical, and magnetic properties. The preparation of MNPs and the development of a superior method suitable for magnetic drug delivery and hyperthermia applications are surveyed. Furthermore, their physicochemical properties and their effects on biocompatibility, biodistribution, and pharmacokinetic behavior, are reported. The functionalization and surface modification of MNPs, which are intensively exploited in cancer treatment, particularly for drug delivery and hyperthermia, are demonstrated. Some studies of the incorporation of MNPs in the diagnosis, treatment, and imaging of cancer are summarized. Furthermore, the effects of combining antineoplastic drugs via drug delivery systems with hyperthermia treatment to achieve an efficient synergetic effect are extensively reviewed. Finally, this review article provides an overview of recent innovations, future challenges, prospects, and developments that advance MNP therapeutic applications, particularly in oncology.

Verified
Journal Article
Open access
PDF file
Heba R. AlrefaeyHeba R. Alrefaey
Heba R. Alrefaey
Saleh A. NaserSaleh A. Naser
Saleh A. Naser
Crohn’s disease (CD) is a chronic inflammatory bowel disease with a rising incidence and prevalence worldwide. It is associated with Mycobacterium avium subspecies paratuberculosis (MAP). Current CD treatment strategies are based on anti-inflammatory therapies, including anti-TNF-α drugs. These treatment options provide short-term benefits and are associated with numerous side effects in CD patients. Manuka honey is distinguished from other honey by its high content of methylglyoxal (MGO). MGO, a reactive metabolite, is also generated endogenously in macrophages during infection through glycolysis; however, the amount is insufficient to neutralize the ongoing infection and subsequent tissue damage. This study examined whether exogenous, low-dose MGO can modulate MAP-driven inflammatory and glycolysis- and lactate-associated markers in infected macrophages. THP-1 macrophages were infected with the CD-associated MAP strain and then treated with MGO doses at defined time intervals. We measured markers of M1-/M2-like phenotype polarization, monocarboxylate transporters, lactate export, antioxidant responses, cytokines, and selected glycolysis- and lactate-associated markers at both the mRNA and protein levels. MGO reduced M1 signaling markers CXCL10 (p < 0.05), TNF-α (p < 0.0001), IL-1β (p < 0.01), and IL-6 (p < 0.0001). Simultaneously, MGO promoted M2 shift, elevating CD206 by 1.20-fold and IL-10 by 7-fold. Low-dose MGO administration was associated with increases in Nrf-2 (1.4-fold), HO-1 (1.4-fold), and IL-1Ra (1.5-fold), while the pro-inflammatory cytokines decreased. Metabolically, MGO downregulated MCT4 (p < 0.01) and reduced lactate export by 30%. These changes were coupled with higher PHD2 (1.4-fold) and decreases in GLUT1 (0.9-fold), PKD1 (0.8-fold), and IL-1β, consistent with attenuated glycolysis- and lactate-associated inflammatory signaling. These results suggest that hormetic concentration of MGO mitigates MAP-induced inflammatory activation while altering glycolysis- and lactate-related signaling markers in infected macrophages. Most importantly, we unraveled the predicted molecular mechanism by which MGO suppresses inflammation and modulates oxidative damage.